JP2018534348A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018534348A5 JP2018534348A5 JP2018534496A JP2018534496A JP2018534348A5 JP 2018534348 A5 JP2018534348 A5 JP 2018534348A5 JP 2018534496 A JP2018534496 A JP 2018534496A JP 2018534496 A JP2018534496 A JP 2018534496A JP 2018534348 A5 JP2018534348 A5 JP 2018534348A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- item
- composition according
- compound
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 3
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 2
- 229910052805 deuterium Inorganic materials 0.000 claims description 2
- 230000000155 isotopic effect Effects 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 238000000034 method Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562221531P | 2015-09-21 | 2015-09-21 | |
| US62/221,531 | 2015-09-21 | ||
| US201562238511P | 2015-10-07 | 2015-10-07 | |
| US62/238,511 | 2015-10-07 | ||
| US201662348855P | 2016-06-10 | 2016-06-10 | |
| US62/348,855 | 2016-06-10 | ||
| PCT/US2016/052922 WO2017053455A1 (en) | 2015-09-21 | 2016-09-21 | Administration of deuterated cftr potentiators |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021034591A Division JP7196217B2 (ja) | 2015-09-21 | 2021-03-04 | 重水素化されたｃｆｔｒ増強剤の投与 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018534348A JP2018534348A (ja) | 2018-11-22 |
| JP2018534348A5 true JP2018534348A5 (enExample) | 2019-11-07 |
| JP6849686B2 JP6849686B2 (ja) | 2021-03-24 |
Family
ID=58387264
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018534496A Active JP6849686B2 (ja) | 2015-09-21 | 2016-09-21 | 重水素化されたｃｆｔｒ増強剤の投与 |
| JP2021034591A Active JP7196217B2 (ja) | 2015-09-21 | 2021-03-04 | 重水素化されたｃｆｔｒ増強剤の投与 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021034591A Active JP7196217B2 (ja) | 2015-09-21 | 2021-03-04 | 重水素化されたｃｆｔｒ増強剤の投与 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20180353500A1 (enExample) |
| EP (2) | EP4292588A3 (enExample) |
| JP (2) | JP6849686B2 (enExample) |
| KR (1) | KR102828163B1 (enExample) |
| CN (1) | CN108367002A (enExample) |
| AU (2) | AU2016326441B2 (enExample) |
| BR (1) | BR112018005454A2 (enExample) |
| CA (1) | CA2998911C (enExample) |
| HK (1) | HK1258472A1 (enExample) |
| IL (2) | IL257993A (enExample) |
| MA (1) | MA42950A (enExample) |
| MX (1) | MX388470B (enExample) |
| RU (1) | RU2761344C2 (enExample) |
| SG (1) | SG10201913588YA (enExample) |
| UA (1) | UA124619C2 (enExample) |
| WO (1) | WO2017053455A1 (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12458635B2 (en) | 2008-08-13 | 2025-11-04 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| HUE047354T2 (hu) | 2011-05-18 | 2020-04-28 | Vertex Pharmaceuticals Europe Ltd | Ivacaftor deuterizált származékai |
| BR112014021090B1 (pt) | 2012-02-27 | 2023-01-24 | Vertex Pharmaceuticals Incorporated | Composição farmacêutica e uso de n-[2,4-bis(1,1-dimetiletil)-5-hidróxifenil]-1,4-di-hidro-4-oxoquinolina3-carboxamida na preparação da mesma |
| IL313498A (en) | 2014-10-06 | 2024-08-01 | Vertex Pharma | Modulators of the cystic fibrosis transmembrane conductance regulator |
| US10196384B2 (en) | 2015-03-31 | 2019-02-05 | Vertex Pharmaceuticals (Europe) Limited | Deuterated CFTR modulators |
| MX388470B (es) | 2015-09-21 | 2025-03-20 | Vertex Pharmaceuticals Europe Ltd | Administración de potenciadores de regulador de la conductancia transmembrana de fibrosis quística (cftr) deuterados. |
| CA2999529A1 (en) | 2015-09-25 | 2017-03-30 | Vertex Pharmaceuticals (Europe) Limited | Deuterated cftr potentiators |
| CA3019380A1 (en) | 2016-03-31 | 2017-10-05 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| JP7061115B2 (ja) | 2016-09-30 | 2022-04-27 | バーテックス ファーマシューティカルズ インコーポレイテッド | 嚢胞性線維症膜コンダクタンス制御因子の調節因子、医薬組成物、処置の方法、及び当該調節因子を作製するためのプロセス |
| RS61150B1 (sr) | 2016-12-09 | 2020-12-31 | Vertex Pharma | Modulator regulatora transmembranske provodljivosti cistične fibroze, farmaceutske kompozicije, postupci lečenja, i postupak za dobijanje modulatora |
| US11253509B2 (en) | 2017-06-08 | 2022-02-22 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| BR112020000941A2 (pt) * | 2017-07-17 | 2020-07-21 | Vertex Pharmaceuticals Incorporated | métodos de tratamento para fibrose cística |
| CA3069225A1 (en) * | 2017-07-17 | 2019-01-24 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| TWI799435B (zh) | 2017-08-02 | 2023-04-21 | 美商維泰克斯製藥公司 | 製備化合物之製程 |
| CA3078893A1 (en) | 2017-10-19 | 2019-04-25 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of cftr modulators |
| KR102768380B1 (ko) | 2017-12-01 | 2025-02-13 | 버텍스 파마슈티칼스 인코포레이티드 | 낭포성 섬유증 막관통 조절 인자의 제조 방법 |
| CN111757874B (zh) | 2017-12-08 | 2024-03-08 | 弗特克斯药品有限公司 | 用于制备囊性纤维化跨膜传导调节因子的调节剂的方法 |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| JP7214743B2 (ja) | 2018-02-15 | 2023-01-30 | バーテックス ファーマシューティカルズ インコーポレイテッド | 嚢胞性線維症膜コンダクタンス制御因子のモジュレーターとしての大環状分子、それらの医薬組成物、嚢胞性線維症の治療におけるそれらの使用、及びそれらの製造方法 |
| EP3774825A1 (en) | 2018-04-13 | 2021-02-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| FI3880197T3 (fi) | 2018-11-14 | 2023-05-04 | Vertex Pharma | Menetelmiä kystisen fibroosin hoitamiseksi |
| UY38630A (es) | 2019-04-03 | 2020-10-30 | Vertex Pharma | Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| WO2020214921A1 (en) | 2019-04-17 | 2020-10-22 | Vertex Pharmaceuticals Incorporated | Solid forms of modulators of cftr |
| FR3096890B1 (fr) | 2019-06-07 | 2021-05-14 | H4 Orphan Pharma | Utilisation d’une molécule opioïde pour traiter l’œil sec et l’œil allergique. |
| WO2021030556A1 (en) | 2019-08-14 | 2021-02-18 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| MX2022001828A (es) | 2019-08-14 | 2022-06-08 | Vertex Pharma | Formas cristalinas de moduladores del regulador de conductancia transmembrana de la fibrosis quistica (cftr). |
| TWI867024B (zh) | 2019-08-14 | 2024-12-21 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
| TWI899097B (zh) | 2019-08-14 | 2025-10-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
| FR3109524B1 (fr) | 2020-04-22 | 2022-04-08 | H4 Orphan Pharma | Utilisation d’un ligand multifonctionnel pour traiter l’œil sec et les dysfonctionnements des glandes de Meibomius et des glandes lacrymales. |
| FR3111071B1 (fr) | 2020-06-04 | 2023-01-13 | H4 Orphan Pharma | Utilisation de ligands multifonctionnels pour traiter les syndromes de détresse respiratoire et le choc cytokinique liés aux infections virales à coronavirus. |
| CR20230120A (es) | 2020-08-07 | 2023-09-01 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| US20230303589A1 (en) | 2020-08-13 | 2023-09-28 | Vertex Pharmaceuticals Incorporated | Crystalline forms of cftr modulators |
| US20230373935A1 (en) | 2020-10-07 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| US20230373939A1 (en) | 2020-10-07 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| US20230365587A1 (en) | 2020-10-07 | 2023-11-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| CN116670143A (zh) | 2020-10-07 | 2023-08-29 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调控因子的调节剂 |
| US20230382924A1 (en) | 2020-10-07 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2022076629A1 (en) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| MX2023004074A (es) | 2020-10-07 | 2023-07-05 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica. |
| WO2022076622A2 (en) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP4225763A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| US12324802B2 (en) | 2020-11-18 | 2025-06-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP4259139A1 (en) | 2020-12-10 | 2023-10-18 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| IL314449A (en) | 2022-02-03 | 2024-09-01 | Vertex Pharma | Methods of treatment for cystic fibrosis |
| WO2023154291A1 (en) | 2022-02-08 | 2023-08-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| PE20250606A1 (es) | 2022-04-06 | 2025-02-26 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica |
| CN119947720A (zh) | 2022-05-16 | 2025-05-06 | 弗特克斯药品有限公司 | 治疗囊性纤维化的方法 |
| WO2025076240A1 (en) | 2023-10-04 | 2025-04-10 | Vertex Pharmaceuticals Incorporated | Solid forms of modulators of cystic fibrosis transmembrane conductance regulator |
| WO2025076235A1 (en) | 2023-10-04 | 2025-04-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2025166342A1 (en) | 2024-02-04 | 2025-08-07 | Vertex Pharmaceuticals Incorporated | Combination of vanzacaftor, tezacaftor, deutivacaftor for use in treating cystic fibrosis |
| EP4648753A1 (en) | 2024-02-07 | 2025-11-19 | Vertex Pharmaceuticals Incorporated | Compositions for the treatment of cftr-mediated diseases |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9925962D0 (en) | 1999-11-02 | 1999-12-29 | Novartis Ag | Organic compounds |
| NZ528689A (en) | 2001-05-03 | 2005-03-24 | F | Pharmaceutical dosage form of amorphous nelfinavir mesylate |
| WO2006039237A1 (en) | 2004-09-29 | 2006-04-13 | Cordis Corporation | Pharmaceutical dosage forms of stable amorphous rapamycin like compounds |
| PL1993360T3 (pl) | 2005-12-28 | 2017-08-31 | Vertex Pharmaceuticals Incorporated | Stałe postacie n-[2,4-bis(1,1-dimetyloetylo)-5-hydroksyfenylo]-1,4- dihydro-4-oksochinolino-3-karboksyamidu |
| SMT201800074T1 (it) | 2008-08-13 | 2018-05-02 | Vertex Pharma | Composizione farmaceutica di n-[2,4-bis(1,1-dimetiletil)-5-idrossifenil]-1,4-diidro-4-ossochinolin-3-carbossammide e sua somministrazione |
| EP2575814A1 (en) | 2010-05-20 | 2013-04-10 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
| HUE047354T2 (hu) | 2011-05-18 | 2020-04-28 | Vertex Pharmaceuticals Europe Ltd | Ivacaftor deuterizált származékai |
| PT2709986T (pt) * | 2011-05-18 | 2017-06-26 | Concert Pharmaceuticals Inc | Derivados deuterados de ivacaftor |
| BR112014021090B1 (pt) | 2012-02-27 | 2023-01-24 | Vertex Pharmaceuticals Incorporated | Composição farmacêutica e uso de n-[2,4-bis(1,1-dimetiletil)-5-hidróxifenil]-1,4-di-hidro-4-oxoquinolina3-carboxamida na preparação da mesma |
| MY178621A (en) * | 2012-11-19 | 2020-10-19 | Vertex Pharmaceuticals Europe Ltd | Deuterated cftr potentiators |
| CN109364075B (zh) * | 2012-11-21 | 2021-10-29 | 顶点制药（欧洲）有限公司 | 氘化cftr增效剂 |
| US20140221424A1 (en) * | 2013-01-30 | 2014-08-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for use in the treatment of cystic fibrosis |
| MX388470B (es) | 2015-09-21 | 2025-03-20 | Vertex Pharmaceuticals Europe Ltd | Administración de potenciadores de regulador de la conductancia transmembrana de fibrosis quística (cftr) deuterados. |
-
2016
- 2016-09-21 MX MX2018003331A patent/MX388470B/es unknown
- 2016-09-21 AU AU2016326441A patent/AU2016326441B2/en active Active
- 2016-09-21 CA CA2998911A patent/CA2998911C/en active Active
- 2016-09-21 JP JP2018534496A patent/JP6849686B2/ja active Active
- 2016-09-21 WO PCT/US2016/052922 patent/WO2017053455A1/en not_active Ceased
- 2016-09-21 HK HK19100788.5A patent/HK1258472A1/zh unknown
- 2016-09-21 UA UAA201804280A patent/UA124619C2/uk unknown
- 2016-09-21 SG SG10201913588YA patent/SG10201913588YA/en unknown
- 2016-09-21 EP EP23191452.4A patent/EP4292588A3/en active Pending
- 2016-09-21 MA MA042950A patent/MA42950A/fr unknown
- 2016-09-21 RU RU2018114447A patent/RU2761344C2/ru active
- 2016-09-21 CN CN201680067707.1A patent/CN108367002A/zh active Pending
- 2016-09-21 KR KR1020187010964A patent/KR102828163B1/ko active Active
- 2016-09-21 BR BR112018005454A patent/BR112018005454A2/pt not_active Application Discontinuation
- 2016-09-21 US US15/761,532 patent/US20180353500A1/en not_active Abandoned
- 2016-09-21 EP EP16849524.0A patent/EP3352757B1/en active Active
-
2018
- 2018-03-08 IL IL257993A patent/IL257993A/en unknown
-
2020
- 2020-05-14 US US15/931,944 patent/US20200375973A1/en active Pending
-
2021
- 2021-03-04 JP JP2021034591A patent/JP7196217B2/ja active Active
-
2022
- 2022-02-21 AU AU2022201135A patent/AU2022201135B2/en active Active
- 2022-03-20 IL IL291517A patent/IL291517A/en unknown